ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,998,000 | -22.7% | 15,500 | 0.0% | 0.02% | -30.0% |
| Q4 2020 | $2,585,000 | +8.1% | 15,500 | 0.0% | 0.03% | -9.1% |
| Q3 2020 | $2,392,000 | +21.6% | 15,500 | +16.5% | 0.03% | +17.9% |
| Q2 2020 | $1,967,000 | +46.8% | 13,300 | +11.8% | 0.03% | +7.7% |
| Q1 2020 | $1,340,000 | +2.3% | 11,900 | -12.5% | 0.03% | +8.3% |
| Q3 2019 | $1,310,000 | -37.5% | 13,600 | -25.3% | 0.02% | -33.3% |
| Q2 2019 | $2,096,000 | -2.1% | 18,200 | 0.0% | 0.04% | -69.5% |
| Q1 2019 | $2,142,000 | – | 18,200 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |